Xerosis and pruritus as major EGFRI-associated adverse events.

Autor: Clabbers JMK; Department of Clinical Oncology, Leiden University Medical Centre, P.O. Box 9600, 2300 RC, Leiden, The Netherlands. juliamkclabbers@gmail.com., Boers-Doets CB; Department of Clinical Oncology, Leiden University Medical Centre, P.O. Box 9600, 2300 RC, Leiden, The Netherlands., Gelderblom H; Department of Clinical Oncology, Leiden University Medical Centre, P.O. Box 9600, 2300 RC, Leiden, The Netherlands., Stijnen T; Department of Medical Statistics and Bioinformatics, Leiden University Medical Centre, P.O. Box 9600, 2300 RC, Leiden, The Netherlands., Lacouture ME; Department of Medicine, Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA., van der Hoeven KJM; Department of Clinical Oncology, Leiden University Medical Centre, P.O. Box 9600, 2300 RC, Leiden, The Netherlands., Kaptein AA; Department of Medical Psychology, Leiden University Medical Centre, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.
Jazyk: angličtina
Zdroj: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2016 Feb; Vol. 24 (2), pp. 513-521. Date of Electronic Publication: 2015 Jun 27.
DOI: 10.1007/s00520-015-2781-y
Abstrakt: Purpose: The objective of this sub-analysis of the BeCet study (NCT01136005) was to examine health-related quality of life (HRQoL) of patients experiencing dermatological adverse events (AEs) during the first 6 weeks of epidermal growth factor receptor inhibitor (EGFRI) treatment.
Methods: Patients (n = 85) treated with EGFRI completed five questionnaires during the first 6 weeks of treatment. 77 patients provided enough data for the sub-analysis. Experienced AEs were reported in the Dermatological Reactions Targeted Therapy-Patients (DERETT-P), a symptom experience diary for patients treated with targeted therapy. The impact of EGFRI-associated dermatological adverse events on HRQoL was examined using four HRQoL questionnaires; the Functional Assessment of Cancer Therapy-EGFRI (FACT-EGFRI-18), the Functional Assessment of Cancer Therapy-General (FACT-G), the 36-Item Short Form Health Survey (SF-36), and the Skindex-16.
Results: During the first 6 weeks of EGFRI treatment, physical discomfort was the most significantly affected domain. In the entire study population, xerosis (dry skin) (22.3 %) and pruritus (itchy skin) (16.9 %) were reported as the most impactful AEs. For patients experiencing a papulopustular eruption (acneiform rash) pruritus (24.2 %), xerosis (18.9 %), and papulopustular eruption (6.3 %) were reported as the most impactful AEs. Papulopustular eruption, xerosis, and pruritus all showed a significant negative effect on HRQoL, displayed in FACT-EGFRI-18 scores.
Conclusions: In addition to papulopustular eruption, xerosis and pruritus are major EGFRI-associated dermatological AEs with an impact on HRQoL, which warrant more attention in clinical practice and research.
Databáze: MEDLINE
Externí odkaz: